Syrosingopine is primarily used in research related to cancer metabolism and multidrug resistance. It has gained attention for its ability to inhibit the cellular efflux of certain chemotherapeutic agents by targeting vesicular monoamine transporters (VMATs), which can enhance the accumulation of drugs in cancer cells. This property makes it a potential candidate for combination therapies aimed at overcoming resistance in tumor cells.

Additionally, syrosingopine has been studied in metabolic reprogramming strategies, particularly in targeting the energy pathways of cancer cells. It interferes with glycolysis and oxidative phosphorylation, disrupting the metabolic adaptability of tumors, especially under hypoxic conditions. These effects position syrosingopine as a tool compound in oncology research, particularly in studies exploring synthetic lethality and dual-inhibitor approaches in cancer treatment.

It is also used in neuroscience research due to its impact on monoamine levels, influencing dopamine and norepinephrine storage and release, which can help in understanding neurotransmitter dynamics and related disorders.

Historically, syrosingopine was used clinically as an antihypertensive agent, working in combination with other drugs to reduce vascular resistance and facilitate cardiac output by relaxing vascular smooth muscle, leading to vasodilation and lowered blood pressure. However, its current primary applications are in research settings.